BSBruno Serrano-Arias

Bruno Serrano-Arias

*This is an algorithmically generated author record based on publicly available information.

Bruno Serrano-Arias has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Diseño de un Sistema de Gestión de Farmacovigilancia en Pacientes Atendidos en el Centro de Investigación y Manejo del Cáncer

    by Bruno Serrano Arias, María Daniela Ramos Chaves, Leonardo García Bermúdez

    El cáncer representa una de las principales causas de mortali- dad en el ámbito mundial, y la alta toxicidad de los tratamientos oncológicos subraya la necesidad de un sólido sistema de farmacovigilancia. Este estudio tuvo como objetivo diseñar un sistema de gestión de eventos adversos en el Centro de Investigación y Manejo del Cáncer (CIMCA), a fin de optimizar la seguridad y adherencia terapéutica de los pacientes. Se trata de un estudio descriptivo cualitativo, fundamentado en encuestas al personal de salud y revisión documental de las prácticas de notificación de eventos adversos. Como resultado, se actualizó el procedimiento estándar de farmacovigilancia incorporando un flujograma de atención y formularios digitales de trazabilidad, registro de eventos adversos e intervenciones clínicas. Se concluye que la implementación de estas herramientas permite una vigilancia más efectiva y un abordaje multidisciplinario que fortalece la seguridad del paciente. Se recomienda capacitar al equipo de salud en el uso de estos recursos y realizar auditorías periódicas para su evaluación continua.

  • Open Access

    A cross-national performance comparison universal healthcare systems of Chile, Costa Rica, Italy, and Spain using OECD data

    by Esteban Zavaleta-Monestel, Andrea Zovi, Jorge Morales-Vallespín, José Manuel Martínez-Sesmero, Zoe Rojas-Barrantes, Bruno Serrano-Arias, Sebastián Arguedas-Chacón, José Pablo Díaz-Madriz, Jorge Arturo Villalobos-Madriz, Roberto Langella, et al.

    Objectives: To analyze Organization for Economic Cooperation and Development (OECD) indicators for the Health Systems of Costa Rica, Spain, and Italy, focusing on year-to-year changes. Study design and methods: Examining each country’s healthcare systems utilizes a value-for-money approach, aiming to outline their healthcare expenditures relative to the OECD average, while also assessing the value obtained from these investments. This involves contrasting reported indicator values for each country and the OECD average during a year close to the last decade’s outset (year 1) with data around 2020 (year 2). Results: Results obtained are based on different indicators and the countries being examined. Costa Rica stood out with lowest healthcare investment, while Chile had the less population coverage for a set core of services. Italy and Spain achieved 100% healthcare coverage. All four regions reported decreased tobacco consumption in terms of non-medical determinants of health. Costa Rica showcased the highest vaccination coverage and experienced the most significant increase in this aspect within healthcare utilization. In the context of resource accessibility, waiting times from specialist assessment to treatment increased the most for hip replacement procedures in Chile, Costa Rica, Italy, and Spain. The Pharmaceutical Consumption analysis highlighted agents acting on the Renin-Angiotensin system as the most widely consumed category. Conclusion: This analysis helps reveal the workings of diverse health systems, allowing us to pinpoint areas for potential improvement within each region. By examining the achievements and obstacles faced by other nations, policymakers and healthcare stakeholders acquire a valuable foundation on which to enact reforms.


  • Open Access

    Effects of clinical interventions through a comprehensive medication management program: A retrospective study among outpatients in a private hospital

    by Esteban Zavaleta-Monestel, Bruno Serrano-Arias, Sebastián Arguedas-Chacón, Alonso Quirós-Romero, José Pablo Díaz-Madriz, Arturo Villalobos-Madriz, Allan Robles-Calderón, Jorge Bucknor-Masís, José Miguel Chaverri-Fernández


  • Reply to comment on “Insights into clinical pharmacy practice in Latin America”

    by Esteban Zavaleta‐Monestel, Bruno Serrano‐Arias, Antonella Milano‐Gil, Cesar Sanchez‐Solis, Dadier Antonio Arroyo‐Monterrosa, Daniel Muñoz‐Pichuante, Jorge Morales‐Vallespin, Jose Pablo Diaz‐Madriz, Mario Viñas‐Veliz, Silvestre Dalmaso‐Neto, et al.

  • Open Access

    Optimizing Heart Failure Management: A Review of the Clinical Pharmacist Integration to the Multidisciplinary Health Care Team

    by Esteban Zavaleta-Monestel, Sebastián Arguedas-Chacón, Alonso Quirós-Romero, José Miguel Chaverri-Fernández, Bruno Serrano-Arias, José Pablo Díaz-Madriz, Jonathan García-Montero, Mario Osvaldo Speranza-Sanchez

    Zavaleta-Monestel E, et al. Int J Heart Fail. 2024 Jan;6(1):1-10. https://doi.org/10.36628/ijhf.2023.0022


  • Open Access

    Bacteremia Following Alkalihalobacillus clausii (Formerly Bacillus clausii) Administration in Immunosuppressed Adults: A Case Series

    by José Pablo Díaz-Madriz, Esteban Zavaleta-Monestel, Carolina Rojas-Chinchilla, Sebastián Arguedas-Chacón, Bruno Serrano-Arias, Mery Alejandra Ferreto-Meza, Betzy María Romero-Chavarría, Priscila Zumbado-Amerling, Ana Fernanda Vásquez-Mendoza, Karla Sofia Gutiérrez-González, et al.

    (1) Background: Given the widespread use of Alkalihalobacillus clausii (A. clausii) as a probiotic in recent decades and the detection of bacteremia cases in a group of patients, we sought to analyze cases of A. clausii bacteremia following oral probiotic use (2) Methods: A retrospective observational study was conducted at a private hospital in San Jose, Costa Rica. Cases of bacteremia caused by A. clausii confirmed by the microbiology laboratory were analyzed in patients who received oral treatment with this probiotic between January 2020 and January 2022. In addition, an isolate (HCB-AC2) was compared through whole genome sequencing to demonstrate the correlation of bacteremia and A. clausii. Possible vulnerability factors related to the development of this condition were determined. (3) Results: Four cases were identified in this hospital over 2 years. Genomic analysis of isolate HCB-AC2, using two different methods, showed identical results. This indicates that HCB-AC2 is genomically identical to ENTpro and the Enterogermina® reference genome. The median age was 71 years, and all patients had some degree of immunosuppression. All patients met at least three sepsis criteria at the time of bacterial identification. Most patients were treated with vancomycin and levofloxacin. Three of the identified patients died. (4) Conclusion: A. clausii can be used as a probiotic, but caution is advised when used in immunosuppressed and elderly patients. These findings align with those reported in similar case studies.


  • A Comprehensive Review of Sulfonamide Hypersensitivity: Implications for Clinical Practice

    by Bruno Serrano-Arias, Adriana Araya-Zúñiga, Johan Waterhouse-Garbanzo, Zoe Rojas-Barrantes, Sebastián Arguedas-Chacón, Esteban Zavaleta-Monestel

    Sulfonamides, which are drugs commonly prescribed in hospital and outpatient settings, have historically been associated with a high incidence of hypersensitivity reactions. It is believed that there is an increased risk of cross-reactions with other drugs that contain this functional group in their structure. However, it has not been conclusively established that the sulfonamide group is the sole cause of hypersensitivity reactions, as non-antibiotic sulfonamides do not share the same accessory groups with antibiotic sulfonamides. Therefore, cross-reactivity between different types of sulfonamides and sulfonamide-type antibiotics is not clearly demonstrated, and allergic reactions may involve other mechanisms. Misinformation about this topic can lead to inappropriate use of alternative antibiotics with lower efficacy or higher adverse effects, contributing to antibiotic resistance. It is crucial to individualize and monitor patients with a history of allergies to sulfonamide-type antibiotics when introducing a new drug containing sulfa and manage any adverse reactions promptly. Desensitization protocols may be a viable option for patients who specifically benefit from these antibiotics, particularly those who are immunosuppressed. This article provides a descriptive bibliographic review to update information on sulfa allergy, its prevalence, management, and recommendations to prevent such reactions and optimize pharmacotherapy, without underusing these drugs.


  • Insights into clinical pharmacy practice in Latin America

    by Esteban Zavaleta‐Monestel, Bruno Serrano‐Arias, Antonella Milano‐Gil, Cesar Sanchez‐Solis, Dadier Antonio Arroyo‐Monterrosa, Daniel Muñoz‐Pichuante, Jorge Morales‐Vallespin, Jose Pablo Diaz‐Madriz, Mario Viñas‐Veliz, Silvestre Dalmaso‐Neto, et al.


  • The direct correlation between Covid-19 and Attention Deficit/Hyperactivity Disorder (ADHD)

    by Francesco Ferrara, Esteban Zavaleta, Antonio Vitiello, Jorge Arturo Villalobos, Andrea Zovi, Roberto Langella, Bruno Serrano, Ugo Trama, Sebastian Arguedas, Eduardo Nava, et al.


  • Open Access

    Farmacoterapia y nuevos tratamientos alternativos para el Síndrome de Ovario Poliquístico.

    by Bruno Serrano Arias, Adriana Araya Zúñiga, Analaura Ramírez Camacho, Michelle Mou Keng

    El Síndrome de ovario poliquístico (SOP) es el desorden endocrinológico más frecuente en mujeres en edad reproductiva y es la causa más importante de infertilidad por anovulación crónica. Al ser una patología de origen multifactorial su abordaje no se encuentra bien definido, por lo que esta revisión tiene como fin explicar los tratamientos disponibles a nivel mundial. La primera línea de tratamiento históricamente utilizada es la modificación del estilo de vida. Los anticonceptivos orales combinados (ACOS) son la primera elección como tratamiento farmacológico y son utilizados para manejo a largo plazo de la patología. Los sensibilizadores de insulina son una alternativa útil en el manejo de la resistencia a la insulina y constituyen una opción idónea para agregar secundariamente a cualquier tratamiento de primera línea. Creciente evidencia científica provee a los prescriptores con nuevas herramientas alternativas como suplementos, nuevos fármacos, probióticos e intervenciones quirúrgicas para abordar multifactorialmente esta afección. Finalmente, se concluye que las terapias discutidas pueden ser utilizadas solas o en conjunto y se resalta la importancia de individualizar el abordaje de cada paciente con las alternativas disponibles más adecuadas.